All In Biotech

Drug Trial Radar · NCT06474299

The Avenues Study: Dual Use Cessation

Dual Use Cessation: A MOST Screening Trial to Identify Effective Interventions to Help People Who Smoke and Vape

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Sep 24, 2024

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overarching goal of this research is to determine the most effective approach for helping dual users of cigarettes and electronic nicotine delivery systems (ENDS) quit smoking. 500 participants will be enrolled and can expect to be on study for 12 months.

Conditions

  • Smoking Cessation
  • Electronic Cigarette Use

Interventions

  • VareniclineDrug

    0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily

  • Nicotine patchDrug

    Following package inserts starting on the TQD, participants who smoke \>10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.

  • Dual Focused Cessation CounselingBehavioral

    Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).

  • Smoking Focused Cessation CounselingBehavioral

    Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).

  • Counseling Intensity: 1 SessionOther

    Participants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD).

  • Counseling Intensity: 4 SessionsOther

    Participants assigned to intensive counseling will have four, 15-20-minute sessions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 52-week biochemically confirmed 7-day point-prevalence abstinence from cigarettesTime frame: up to 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Wisconsin-Madison School of Medicine and Public Health

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.